These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
308 related articles for article (PubMed ID: 18273760)
1. [Cost-effectiveness evaluation of predictive molecular diagnostics using the example of hereditary non-polyposis colorectal cancer (HNPCC)]. Hagen A; Hessabi HK; Gorenoi V; Schönermark MP Gesundheitswesen; 2008 Jan; 70(1):18-27. PubMed ID: 18273760 [TBL] [Abstract][Full Text] [Related]
2. The relevance of unrelated costs internal and external to the healthcare sector to the outcome of a cost-comparison analysis of secondary prevention: the case of general colorectal cancer screening in the German population. Tscheulin DK; Drevs F Eur J Health Econ; 2010 Apr; 11(2):141-50. PubMed ID: 19449159 [TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of surveillance programs for families at high and moderate risk of hereditary non-polyposis colorectal cancer. Olsen KR; Bojesen SE; Gerdes AM; Lindorff-Larsen K; Bernstein IT Int J Technol Assess Health Care; 2007; 23(1):89-95. PubMed ID: 17234021 [TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis on screening for colorectal neoplasm and management of colorectal cancer in Asia. Tsoi KK; Ng SS; Leung MC; Sung JJ Aliment Pharmacol Ther; 2008 Aug; 28(3):353-63. PubMed ID: 18638075 [TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of screening for colorectal cancer in France using a guaiac test versus an immunochemical test. Lejeune C; Dancourt V; Arveux P; Bonithon-Kopp C; Faivre J Int J Technol Assess Health Care; 2010 Jan; 26(1):40-7. PubMed ID: 20059779 [TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of colorectal cancer screening in renal transplant recipients. Wong G; Howard K; Craig JC; Chapman JR Transplantation; 2008 Feb; 85(4):532-41. PubMed ID: 18347531 [TBL] [Abstract][Full Text] [Related]
7. Cost effectiveness of a new strategy to identify HNPCC patients. Kievit W; de Bruin JH; Adang EM; Severens JL; Kleibeuker JH; Sijmons RH; Ruers TJ; Nagengast FM; Vasen HF; van Krieken JH; Ligtenberg MJ; Hoogerbrugge N Gut; 2005 Jan; 54(1):97-102. PubMed ID: 15591512 [TBL] [Abstract][Full Text] [Related]
8. High participation rates are not necessary for cost-effective colorectal cancer screening. Howard K; Salkeld G; Irwig L; Adelstein BA J Med Screen; 2005; 12(2):96-102. PubMed ID: 15949121 [TBL] [Abstract][Full Text] [Related]
9. [Juvenile obesity and comorbidity type 2 diabetes mellitus (T2 DM) in Germany: development and cost-of-illness analysis]. Wolfenstetter SB Gesundheitswesen; 2006 Oct; 68(10):600-12. PubMed ID: 17099820 [TBL] [Abstract][Full Text] [Related]
10. The cost-effectiveness of routine office-based identification and subsequent medical treatment of primary open-angle glaucoma in the United States. Rein DB; Wittenborn JS; Lee PP; Wirth KE; Sorensen SW; Hoerger TJ; Saaddine JB Ophthalmology; 2009 May; 116(5):823-32. PubMed ID: 19285730 [TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis in colorectal cancer using a semi-Markov model. Castelli C; Combescure C; Foucher Y; Daures JP Stat Med; 2007 Dec; 26(30):5557-71. PubMed ID: 18058847 [TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of the genetic screening program for familial hypercholesterolemia in The Netherlands. Wonderling D; Umans-Eckenhausen MA; Marks D; Defesche JC; Kastelein JJ; Thorogood M Semin Vasc Med; 2004 Feb; 4(1):97-104. PubMed ID: 15199439 [TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of human papillomavirus vaccination in Belgium: do not forget about cervical cancer screening. Thiry N; De Laet C; Hulstaert F; Neyt M; Huybrechts M; Cleemput I Int J Technol Assess Health Care; 2009 Apr; 25(2):161-70. PubMed ID: 19366497 [TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis in the clinical management of patients with known or suspected lung cancer: [18F]fluorodeoxyglucose PET and CT comparison. Mansueto M; Grimaldi A; Torbica A; Pepe G; Giovacchini G; Messa C; Fazio F Q J Nucl Med Mol Imaging; 2007 Sep; 51(3):224-34. PubMed ID: 17538525 [TBL] [Abstract][Full Text] [Related]
15. Costs and cost effectiveness of a health care provider-directed intervention to promote colorectal cancer screening among Veterans. Wolf MS; Fitzner KA; Powell EF; McCaffrey KR; Pickard AS; McKoy JM; Lindenberg J; Schumock GT; Carson KR; Ferreira MR; Dolan NC; Bennett CL J Clin Oncol; 2005 Dec; 23(34):8877-83. PubMed ID: 16314648 [TBL] [Abstract][Full Text] [Related]
16. Should female relatives of factor V Leiden carriers be screened prior to oral contraceptive use? A cost-effectiveness analysis. Smith KJ; Monsef BS; Ragni MV Thromb Haemost; 2008 Sep; 100(3):447-52. PubMed ID: 18766261 [TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis for determining optimal cut-off of immunochemical faecal occult blood test for population-based colorectal cancer screening (KCIS 16). Chen LS; Liao CS; Chang SH; Lai HC; Chen TH J Med Screen; 2007; 14(4):191-9. PubMed ID: 18078564 [TBL] [Abstract][Full Text] [Related]
18. Evaluating adolescents in juvenile detention facilities for urogenital chlamydial infection: costs and effectiveness of alternative interventions. Mrus JM; Biro FM; Huang B; Tsevat J Arch Pediatr Adolesc Med; 2003 Jul; 157(7):696-702. PubMed ID: 12860793 [TBL] [Abstract][Full Text] [Related]
19. Colon cancer prevention in Italy: cost-effectiveness analysis with CT colonography and endoscopy. Hassan C; Zullo A; Laghi A; Reitano I; Taggi F; Cerro P; Iafrate F; Giustini M; Winn S; Morini S Dig Liver Dis; 2007 Mar; 39(3):242-50. PubMed ID: 17112797 [TBL] [Abstract][Full Text] [Related]
20. Testing for occult cancer in patients with idiopathic deep vein thrombosis--a decision analysis. Barosi G; Marchetti M; Dazzi L; Quaglini S Thromb Haemost; 1997 Nov; 78(5):1319-26. PubMed ID: 9408012 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]